During the SFN 2024 edition in Chicago, Dr. Quentin Marlier, head of biology at Dendrogenix, will present a poster publication called “Improvement of neurological outcomes following Stroke or traumatic brain injury in mice treated with a novel first-in-class compound” to expose preclinical data regarding its lead compound DX243 in stroke and TBI model.
Founded in 2018, Dendrogenix develop first-in-class molecules, Dendrogenins, to address high unmet medical needs in hearing loss and neurology.
© 2024 Dendrogenix
Avenue de l’Hôpital, 11
SPS Bâtiment 34, 3e étage
4000 Liège
Belgium